4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0000950170-24-009505
Chief Executive Officer sold 50,000 shares at an average $60.51 ($3,025,573)
- Chief Executive Officer acquired 50,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Kulkarni Samarth Chief Executive Officer | 2024-01-29 | Option exercise 10b5-1 | +50,000 | $19.12 | $956,000 | 237,377 | D |
| Kulkarni Samarth Chief Executive Officer | 2024-01-29 | Sale 10b5-1 | −49,300 | $60.50 | $2,982,803 | 188,077 | D |
| Kulkarni Samarth Chief Executive Officer | 2024-01-29 | Sale 10b5-1 | −700 | $61.10 | $42,770 | 187,377 | D |
| Derivatives | |||||||
| Kulkarni Samarth Chief Executive Officer | 2024-01-29 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −50,000 | 100,000 | D | ||
| Open-market sales · 50,000 sh · avg $60.51 · $3,025,573 | |||||||
Loading xslF345X05/ownership.xml…